Study Finds Three Predictors of Pain and Fatigue in Elderly

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

EAST LANSING, Michigan-A study of 841 patients age 65 and older newly diagnosed with breast, colon, lung, or prostate cancer found three predictors of pain and fatigue: advanced stage, more comorbid conditions, and lung cancer, compared with breast cancer (the reference), according to researchers from Michigan State University.

EAST LANSING, Michigan—A study of 841 patients age 65 and older newly diagnosed with breast, colon, lung, or prostate cancer found three predictors of pain and fatigue: advanced stage, more comorbid conditions, and lung cancer, compared with breast cancer (the reference), according to researchers from Michigan State University.

Patients were observed at intake and at 12 to 16, 24 to 30, and 52 weeks. The researchers found that pain and fatigue decreased at each observation over the course of the year of follow-up. Fatigue was more commonly reported than pain (30% vs10%) over the year.

No link was found between advancing age and pain and/or fatigue. After controlling for other variables, women were significantly more likely than men to experience pain and/or fatigue, but this may have been confounded by the fact that the prostate cancer patients were significantly less likely to report either pain or fatigue than the breast patients.

Surgery and radiotherapy were significantly associated with pain and fatigue, and chemotherapy was significantly associated with fatigue, but only within the first 40 days after concluding treatment.

Pain and fatigue correlated with a higher mean number of other symptoms (6 vs 2.5 for those without pain or fatigue). "This fact speaks very strongly to the importance of managing these two symptoms," said lead author Charles Given, PhD (J Pain Symptom Manage 21:456-466, 2001).

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content